Alkynyl nucleoside analogs as inhibitors of human rhinovirus

Patent metadata

Field	Value
Publication number	US-10428105-B2
Application number	US-201815974469-A
Country	US
Kind code	B2
Filing date	May 8, 2018
Priority date	Mar 24, 2016
Publication date	Oct 1, 2019
Grant date	Oct 1, 2019

Abstract

The present invention provides a compound of Formula (I) or a salt thereof;

and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.

First claim

The invention claimed is:

1. The compound:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

3. A combination comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.

4. A method of treating an HRV infection or a chikungunya infection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

5. The compound:

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound of claim 5 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

7. A combination comprising a therapeutically effective amount of a compound according to claim 5 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.

8. A method of treating an HRV infection or a chikungunya infection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 5 or a pharmaceutically acceptable salt thereof.

9. The compound:

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound of claim 9 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

11. A combination comprising a therapeutically effective amount of a compound according to claim 9 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.

12. A method of treating an HRV infection or a chikungunya infection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 9 or a pharmaceutically acceptable salt thereof.

13. The compound:

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of claim 13 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

15. A combination comprising a therapeutically effective amount of a compound according to claim 13 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.

16. A method of treating an HRV infection or a chikungunya infection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 13 or a pharmaceutically acceptable salt thereof.

Assignees

• Novartis Ag

Inventors

• Fenaux Martijn
• Saunders Oliver
• Yokokawa Fumiaki
• Zhong Weidong

Classifications

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07H19/14 Primary

  Pyrrolo-pyrimidine radicals · CPC title

• A61K31/7064

  containing condensed or non-condensed pyrimidines · CPC title

• C07D487/04

  Ortho-condensed systems · CPC title